A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02618382|
Recruitment Status : Unknown
Verified December 2016 by Madelon Petersen, St. Joseph's Hospital and Medical Center, Phoenix.
Recruitment status was: Recruiting
First Posted : December 1, 2015
Last Update Posted : December 13, 2016
|Condition or disease||Intervention/treatment||Phase|
|Subdural Hematoma||Drug: Tranexamic Acid||Phase 4|
Chronic subdural hematomas are a common problem faced by neurosurgery with an annual incidence of 13.5/100,00 persons per year and up to 58/100,000 in the over 65 years old population. Their treatment is often complicated by recurrence with rates reported as high as 33%. Currently there is no good strategy to help avoid this problem, which adds significantly to patient morbidity. The pathogenesis of this problem is believed to be related to the propensity of the associated neo-membranes to bleed. It has been shown with labeled red blood cells that bleeding continues to occur into the hematoma cavity. It has also been shown that there are high levels of tissue plasminogen activator in the outer membrane of chronic subdural hematomas. It has been found that ratio of tissue plasminogen activator to plasminogen activator inhibitor contributed to the pathogenesis. It has also been shown that chronic subdural hematomas have high levels of fibrin degradation products which in addition to marking the breakdown of fibrin are themselves antihemostatic by enhancing tissue plasminogen activator activity, having an antithrombin affect and inhibiting platelet aggregation and fibrin polymerization. Essentially, a scenario of ongoing hemorrhage and repeated clot formation and hyperfibrinolysis leads to the expansion and recurrence of chronic subdural hematomas.
Given the importance of plasmin and hyperfibrinolysis in the pathophysiology of chronic subdural hematomas, interrupting its action and the vicious cycle it propagates seems an ideal therapeutic target. Tranexamic acid is a synthetic lysine amino acid derivative. It binds to the fibrin binding sites on plasmin or plasminogen and prevents its interaction and degradation of fibrin. This effect on the neo-membranes of chronic subdural hematomas should prevent rebleeding and the reaccumulation of the subdural hematoma.
Tranexamic acid has been shown to be safe and effective in reducing blood loss and transfusions in a number of types of surgery, reduced mortality and need for urgent surgery in patients with GI bleeding, and reduced bleeding associated with menorrhagia and pregnancy. Adverse effects are generally mild. Thought there is a theoretical increased risk of thromboembolic complications, multiple randomized controlled trials have not shown an increased risk. Furthermore, in a study of over 3000 gynecologic patients using tranexamic acid, there were no thromboembolic complications. This is likely because tranexamic acid has been shown to not have an effect on plasminogen in the vein wall.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||November 2015|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||January 2018|
Experimental: All subjects
Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
Drug: Tranexamic Acid
1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
- Medication Related Complications [ Time Frame: 30 days ]occurrence of stroke, myocardial infarction, deep vein thrombosis, and/or pulmonary embolism
- Postoperative hematoma expansion assessed by preoperative CT comparing width of hematoma to postoperative CTs [ Time Frame: postoperative days 1, 3, 7, and 30+/-7 days ]preoperative CT comparing width of hematoma to postoperative CTs
- Modified Rankin Scale (mRS) [ Time Frame: preoperative (Day 0) and postoperative (day 30) ]postoperative score will equal or exceed preoperative score
- National Institute of Health Stroke Scale (NIHSS) [ Time Frame: immediately preoperative (Day 0) and discharge (up to 30 days postoperative) ]postoperative score will equal or exceed preoperative score
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02618382
|Contact: Heidi Jahnke, RN, MSNfirstname.lastname@example.org|
|United States, Arizona|
|Barrow Brain and Spine||Recruiting|
|Phoenix, Arizona, United States, 85013|
|Contact: Heidi Jahnke, RN, MSN 602-406-6976 email@example.com|
|Principal Investigator: Andrew S Little, MD|
|Sub-Investigator: Rami Almefty, MD|
|Principal Investigator:||Andrew S Little, MD||Barrow Brain and Spine, Phoenix, AZ|